AU6199299A - Method for treating schizophrenia and means used in said method - Google Patents
Method for treating schizophrenia and means used in said method Download PDFInfo
- Publication number
- AU6199299A AU6199299A AU61992/99A AU6199299A AU6199299A AU 6199299 A AU6199299 A AU 6199299A AU 61992/99 A AU61992/99 A AU 61992/99A AU 6199299 A AU6199299 A AU 6199299A AU 6199299 A AU6199299 A AU 6199299A
- Authority
- AU
- Australia
- Prior art keywords
- nicotine
- medical device
- pharmaceutically acceptable
- acceptable salt
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000000980 schizophrenia Diseases 0.000 title claims description 23
- 238000000034 method Methods 0.000 title claims description 20
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 52
- 229960002715 nicotine Drugs 0.000 claims description 49
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 15
- 210000002381 plasma Anatomy 0.000 claims description 6
- 229940126601 medicinal product Drugs 0.000 claims description 3
- 238000001671 psychotherapy Methods 0.000 claims description 3
- 238000013160 medical therapy Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 9
- 239000010410 layer Substances 0.000 description 8
- 208000004547 Hallucinations Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 206010026749 Mania Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000012153 long-term therapy Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930182840 (S)-nicotine Natural products 0.000 description 1
- IOGOPUMIBWOQBJ-UHFFFAOYSA-N 2,2-dimethylpropanoic acid 3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound C(C(C)(C)C)(=O)O.N1=CC=CC(=C1)C1N(C)CCC1 IOGOPUMIBWOQBJ-UHFFFAOYSA-N 0.000 description 1
- VWTHFJXLFGINSW-PPHPATTJSA-N 2-hydroxypropanoic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound CC(O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 VWTHFJXLFGINSW-PPHPATTJSA-N 0.000 description 1
- DEQLKLBWMZRSHN-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;pentanoic acid Chemical compound CCCCC(O)=O.CN1CCCC1C1=CC=CN=C1 DEQLKLBWMZRSHN-UHFFFAOYSA-N 0.000 description 1
- HDJBTCAJIMNXEW-PPHPATTJSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;hydrochloride Chemical compound Cl.CN1CCC[C@H]1C1=CC=CN=C1 HDJBTCAJIMNXEW-PPHPATTJSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- YHBIGBYIUMCLJS-UHFFFAOYSA-N 5-fluoro-1,3-benzothiazol-2-amine Chemical compound FC1=CC=C2SC(N)=NC2=C1 YHBIGBYIUMCLJS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000009810 Catatonic Schizophrenia Diseases 0.000 description 1
- 208000032538 Depersonalisation Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010019070 Hallucination, auditory Diseases 0.000 description 1
- 206010019075 Hallucination, visual Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010028403 Mutism Diseases 0.000 description 1
- 206010028916 Neologism Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000036754 Schizophrenia, catatonic type Diseases 0.000 description 1
- 208000036753 Schizophrenia, disorganised type Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
WO 00/23077 PCT/EP99/07320 Method for treating schizophrenia, and means for use in this method The invention is directed at a method and a device for 5 treating schizophrenia. Schizophrenia is a psychological disorder which was first described as a disease by E. Kraepelin by summarizing individual features, for example of 10 paranoid and catatonic states. The main deficit on which this illness is based is a splitting of psychological functions. However, the appearance of schizophrenia varies, and the diverse symptoms vary in the intensity and combination in which they occur. 15 Typical forms are paranoid hallucinatory schizophrenia, catatonic schizophrenia, schizophrenia simplex and hebephrenia. Symptoms of schizophrenia are, inter alia, disturbances of the thought process, disturbances of thought contents, hallucinations, so-called "ego 20 disturbances", emotional disturbances (disturbances of affect) and disturbances of movement and drive. Schizoaffective psychoses occupy a middle position between schizophrenias and cyclothymias. 25 In cases of schizophrenia a distinction is made between basic symptoms and accessory symptoms. The basic symptoms include disturbances of thought (incoherence of thought, interruption of thought, alterations in the chain of thought), affective disturbances (apathy, 30 hypersensitivity, irritability, loss of contact, ambivalence of feelings) and disturbances of the perception of self (depersonalization, experiences of alienation and of being influenced, splitting of personality) . The accessory symptoms (positive 35 symptoms) include hallucinations (auditory, visual, olfactory and gustatory hallucinations), mania (persecution mania, toxicomania, sex mania inter alia), disturbances of motor responses and of drive -2 (immobility, mutism, athymia) and speech changes (mannerisms, bizarre modes of expression, neologisms, continual repetition). 5 A more detailed description of the pathological states is to be found in B. Bondy: "Was ist Schizophrenie". Verlag C.H. Beck, Munich (1994), the complete contents of which are incorporated herein by reference. 10 For the distinction from other diseases, reference is made to the diagnostic criteria listed in the International Classification of Diseases and in the Diagnostic and Statistical Manual of Mental Disorders. 15 Schizophrenia is regarded as incurable, i.e. a causative treatment is regarded as impossible - as is the case, moreover, for many organic disorders such as, for example, diabetes. However, palliative treatment is possible, so that the symptoms in most of the patients 20 can be suppressed at least to such an extent that hospitalization is unnecessary and the patient is made capable of a controlled everyday life. Before the second world war, medical treatment mainly 25 consisted of administration of hypnotics and other substances for sedation. In addition, physical measures had the aim of calming the patient through physical exhaustion. The patients were for this purpose mainly confined in psychiatric establishments. 30 Medical treatment was extended by use of chlorpromazine, and this substance became a starting point for the development of substances with antipsychotic activity, called neuroleptics. However, 35 these substances have a number of unwanted side effects. Recently, methods for treating schizophrenia by use of nicotine-containing chewing-gum (L.E. Adler et al., - 3 Biol. Psychiatry, 32 (1992) 607-616) and by intestinal absorption (Rhodes et al., WO 98/02188) have been disclosed. 5 The invention is thus based on the object of providing a method and a medicinal product which makes symptom minimizing treatment possible for patients with schizophrenia and is suitable for use in addition to or within the framework of psychotherapy and/or 10 sociotherapy, by which means it is possible to reduce or avoid the disadvantages of treatment with neuroleptics or other substances with psychological activity. It is also intended to avoid the weaknesses of intermittent nicotine uptake by use of nicotine 15 chewing-gum and the disadvantages the irritant effect of nicotine on the mucous membranes on oral administration. The object is achieved by a method and a medicinal 20 product which is suitable for continuous administration of nicotine, preferably onto and through the skin over a prolonged, for example over a 16- or 24-hour, and preferably over a more than 1 day, for example 3-day, period. 25 Medicinal products of this type are known, for example from European patents EP 261 402, EP 289 342, EP 387 694, EP 400 078, EP 427 741 and EP 708 627. These are transdermal therapeutic systems (TTS), which 30 deliver the active ingredient nicotine over a 16-hour (EP 400 078) or a 24-hour period. According to the teaching of these patents, the full contents of which are incorporated herein by reference, it is possible to produce TTSs which are also able to deliver the active 35 ingredient nicotine over a longer period, for example 3 days. For this purpose it is merely necessary to suit the active ingredient content and the thickness of the active ingredient-containing matrix, and the skin -4 contact area of the TTS type used, to the required time of use. The release characteristics of various commercially 5 available nicotine TTSs are described in H. Ho et al., Drug Development and Industrial Pharmacy, 19 (3), 295-313 (1993). The active ingredient nicotine means the naturally 10 occurring (-)-nicotine. Nicotine has two nitrogen atoms. The pharmaceutically acceptable salts of nicotine include the monosalts of salicylic acid, of phenylpropionic acid or of dodecanoic acid. Also preferred as active ingredient are nicotine 15 monoacetate, nicotine sulfate, nicotine hydrochloride, nicotine valerate, nicotine pivalate, nicotine lactate etc. This list cannot, of course, be complete. It is also suitable to mix nicotine (as free base) with 20 a nicotine salt as active ingredient. This may be the case if the planned duration of use is relatively long. This is because free nicotine base permeates more quickly through the skin than do many nicotine salts. After a certain time, this leads to exhaustion of the 25 nicotine in the active ingredient reservoir of the TTS. The nicotine salt content in the active ingredient reservoir is exhausted more slowly than is the free base in the active ingredient reservoir. The salt then plays a greater part in the delivery of nicotine and 30 the maintenance of the nicotine level in the blood plasma at a later time in the use of the TTS. The constructional elements of the TTS are a backing layer, an active ingredient-containing layer and a 35 layer which brings about adhesion to the skin. It is moreover possible for the TTS to have a structure such that the functions of "active ingredient-containing layer" and "layer bringing about adhesion to the skin" are achieved in a single layer.
A further possibility is for the TTS to have a control membrane located between the active ingredient reservoir and the layer bringing about the adhesion to 5 the skin. The control membrane has. the function of controlling the rate of release of the active ingredient from the TTS. The active ingredient may also be present in micro 10 encapsulated form in the active ingredient-containing layer. In this case, the capsule material enveloping the active ingredient would then take over this release-controlling function. 15 The backing layer is impermeable to the active ingredient and is preferably impermeable to light and oxygen, in order to prevent chemical decomposition of the active ingredient by substances penetrating in from the outside. 20 The TTS may also have separate active ingredient reservoirs in a surrounding matrix. The TTS is able to reach a nicotine level in the blood 25 plasma above 2 ng/ml within a period of 4 hours after application. A TTS is also suitable for reaching an essentially constant nicotine level in the blood plasma of between 30 2 and 20 ng/ml after completion of a period of 4 hours after application. A preferred TTS is one suitable for reaching an essentially constant nicotine level in the blood plasma of between 2 and 10 ng/ml after completion of a period of 4 hours after application. 35 The method for treating schizophrenia consists of sticking a TTS according to the invention onto the patient's skin and removing it again after the intended duration of use. This duration of use of a single TTS -6 may be 16 hours or 24 hours. TTS for more than one day, for example for three days of use, are also suitable. Long-term therapy is worthwhile, i.e. use of such nicotine TTS according to the invention designed to 5 last months or years where appropriate. This type of medical long-term therapy by use of transdermally supplied nicotine can be applied at the same time as psychotherapy and/or sociotherapy and/or 10 medical therapy, in particular with medicines which specifically block dopamine receptors (olanzapine, risperidone etc.).
Claims (19)
1. Use of nicotine and/or a pharmaceutically acceptable salt of nicotine for producing a 5 medicinal product for transdermal administration of nicotine and/or a pharmaceutically acceptable salt of nicotine for treating schizophrenia.
2. Medical device for the transdermal administration 10 of nicotine and/or a pharmaceutically acceptable salt of nicotine for use for treating schizophrenia.
3. Medical device according to Claim 2, characterized 15 in that the nicotine and/or a pharmaceutically acceptable salt of nicotine is delivered continuously over a period of at least 16 hours.
4. Medical device according to Claim 2, characterized 20 in that the nicotine and/or a pharmaceutically acceptable salt of nicotine is delivered continuously over a period of at least 24 hours.
5. Medical device according to Claim 2, characterized 25 in that the nicotine and/or a pharmaceutically acceptable salt of nicotine is delivered continuously over a period of at least 3 days.
6. Medical device according to Claim 2, characterized 30 in that it is suitable for reaching a nicotine level in the blood plasma above 2 ng/ml within a period of 4 hours after application.
7. Medical device according to Claim 2, characterized 35 in that it is suitable for reaching an essentially constant nicotine level in the blood plasma of between 2 and 20 ng/ml after completion of a period of 4 hours after application. -8
8. Medical device according to Claim 2, characterized in that it comprises a backing layer which is impermeable to nicotine and/or a pharmaceutically 5 acceptable salt of nicotine, and a layer comprising nicotine and/or a pharmaceutically acceptable salt of nicotine.
9. Medical device according to Claim 2, characterized 10 in that it comprises a layer which brings about adhesion of the device to the patient's skin.
10. Method for treating schizophrenia, characterized in that nicotine and/or a pharmaceutically 15 acceptable salt of nicotine is administered transdermally.
11. Method according to Claim 10, characterized in that nicotine and/or a pharmaceutically acceptable 20 salt of nicotine is administered continuously over a period of at least 16 hours.
12. Method according to Claim 10, characterized in that nicotine and/or a pharmaceutically acceptable 25 salt is administered continuously over a period of at least 24 hours.
13. Method according to Claim 10, characterized in that nicotine and/or a pharmaceutically acceptable 30 salt is administered continuously over a period of at least 3 days.
14. Method for treating schizophrenia, characterized in that a medical device according to Claim 2 is 35 applied to the patient's skin and detached again after a wearing time of 16 hours.
15. Method for treating schizophrenia, characterized in that a medical device according to Claim 2 for -9 transdermal or transmucosal administration of nicotine and/or a pharmaceutically acceptable salt of nicotine is applied to the patient's skin and detached again after a wearing time of 24 hours. 5
16. Method for treating schizophrenia, characterized in that a medical device according to Claim 2 is applied to the patient's skin and detached again after a wearing time of 3 days. 10
17. Method for treating schizophrenia, characterized in that a medical device according to Claim 6 is applied. 15
18. Method for treating schizophrenia, characterized in that a medical device according to Claim 7 is applied.
19. Method according to Claim 10, characterized in 20 that it is applied at the same time as psychotherapy and/or sociotherapy and/or medical therapy.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19847715 | 1998-10-16 | ||
| DE19847715A DE19847715A1 (en) | 1998-10-16 | 1998-10-16 | Treatment of schizophrenia symptoms without side effects, by transdermal administration of nicotine or its salt |
| PCT/EP1999/007320 WO2000023077A1 (en) | 1998-10-16 | 1999-10-02 | Method for treating schizophrenia and means used in said method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU6199299A true AU6199299A (en) | 2000-05-08 |
Family
ID=7884666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU61992/99A Abandoned AU6199299A (en) | 1998-10-16 | 1999-10-02 | Method for treating schizophrenia and means used in said method |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1121126A1 (en) |
| JP (1) | JP2002527478A (en) |
| KR (1) | KR20010080135A (en) |
| CN (1) | CN1323210A (en) |
| AR (1) | AR020815A1 (en) |
| AU (1) | AU6199299A (en) |
| BR (1) | BR9914570A (en) |
| CA (1) | CA2341855A1 (en) |
| DE (1) | DE19847715A1 (en) |
| WO (1) | WO2000023077A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10110953A1 (en) * | 2001-03-07 | 2002-09-19 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for the administration of partial dopamine D2 agonists |
| KR20060120156A (en) * | 2003-10-28 | 2006-11-24 | 알자 코포레이션 | Method and apparatus for reducing the frequency of use of tobacco |
| IL177071A0 (en) * | 2005-08-01 | 2006-12-10 | Nitto Denko Corp | Method of preparing a nicotine transdermal preparation |
| US20140155429A1 (en) * | 2011-05-09 | 2014-06-05 | Envivo Pharmaceuticals, Inc. | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine |
| CZ309812B6 (en) * | 2021-05-25 | 2023-11-01 | Consumer Brands International s.r.o | A mixture for the production of nicotine pouches and a method of its production |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680172A (en) * | 1985-03-05 | 1987-07-14 | Ciba-Geigy Corporation | Devices and methods for treating memory impairment |
| US4915950A (en) * | 1988-02-12 | 1990-04-10 | Cygnus Research Corporation | Printed transdermal drug delivery device |
| GB9614902D0 (en) * | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| US5776956A (en) * | 1996-07-30 | 1998-07-07 | Lectec Corporation | Use of cotinine in treating psychiatric disorders |
| US5776957A (en) * | 1996-11-15 | 1998-07-07 | The University Of Kentucky Research Foundation | Nornicotine enantiomers for use as a treatment for dopamine related conditions and disease states |
-
1998
- 1998-10-16 DE DE19847715A patent/DE19847715A1/en not_active Withdrawn
-
1999
- 1999-10-02 EP EP99948923A patent/EP1121126A1/en not_active Ceased
- 1999-10-02 KR KR1020017004649A patent/KR20010080135A/en not_active Withdrawn
- 1999-10-02 AU AU61992/99A patent/AU6199299A/en not_active Abandoned
- 1999-10-02 CN CN99812210A patent/CN1323210A/en active Pending
- 1999-10-02 WO PCT/EP1999/007320 patent/WO2000023077A1/en not_active Ceased
- 1999-10-02 CA CA002341855A patent/CA2341855A1/en not_active Abandoned
- 1999-10-02 BR BR9914570-7A patent/BR9914570A/en not_active IP Right Cessation
- 1999-10-02 JP JP2000576851A patent/JP2002527478A/en active Pending
- 1999-10-14 AR ARP990105204A patent/AR020815A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE19847715A1 (en) | 2000-04-20 |
| KR20010080135A (en) | 2001-08-22 |
| CA2341855A1 (en) | 2000-04-27 |
| BR9914570A (en) | 2001-07-03 |
| EP1121126A1 (en) | 2001-08-08 |
| WO2000023077A1 (en) | 2000-04-27 |
| AR020815A1 (en) | 2002-05-29 |
| JP2002527478A (en) | 2002-08-27 |
| CN1323210A (en) | 2001-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU660336B2 (en) | Device for the transdermal administration of melatonin | |
| Lehmann et al. | Transdermal fentanyl: clinical pharmacology | |
| EP0641561B1 (en) | Medical device for the administration of active ingredients or drugs at very low doses, particularly homeopathic drugs | |
| NO954925D0 (en) | Method of treating pain by administration of 24 hour oral opioid formulations exhibiting rapid rise in plasma drug level | |
| IL166070A0 (en) | Hot-melt tts for administering rotigotine | |
| NO20120563L (en) | Use of buprenorphine in the manufacture of a medicament | |
| AU1738800A (en) | Dosage formulations for acetylcholinesterase inhibitors | |
| Letechipı́a-Vallejo et al. | Neuroprotective effect of melatonin on brain damage induced by acute global cerebral ischemia in cats | |
| AU6199299A (en) | Method for treating schizophrenia and means used in said method | |
| JPH09506331A (en) | Therapeutic system for psoriasis treatment | |
| CN105025880A (en) | Galenic form for administering the active ingredient | |
| US6143320A (en) | Method for the application of an active substance patch for controlling or alleviating an addiction | |
| KR20040101406A (en) | Pharmaceutical formulation comprising melatonin | |
| Stanley | Anesthesia for the 21st century | |
| US20220040120A1 (en) | Pharmaceutical formulations containing gaboxadol for therapeutic treatment | |
| KR20000029523A (en) | Formulation for the treatment and/or prophylaxis of dementia | |
| JPH0474135A (en) | Eye drop composition | |
| WO2007095605A2 (en) | Method for accelerating reentrainment of a circadian rhythm | |
| AU2014271188A1 (en) | Treatment of neurological and other disorders | |
| KR100736016B1 (en) | Medicament and method for reducing alcohol and/or tobacco consumption | |
| KR100529843B1 (en) | Blister containing a transdermal therapeutic system and a single dose form of administration | |
| Zech et al. | Transdermal (TTS) fentanyl in cancer pain management | |
| HK1062402B (en) | Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops | |
| Fujita et al. | A clinical experience of fosfomycin tablet on cystitis | |
| MXPA99007798A (en) | Sustained analgesia achieved with buprenorphine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |